242 related articles for article (PubMed ID: 32128919)
1. Clinical and molecular insights into BCG immunotherapy for melanoma.
Kremenovic M; Schenk M; Lee DJ
J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium bovis BCG in metastatic melanoma therapy.
Benitez MLR; Bender CB; Oliveira TL; Schachtschneider KM; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7903-7916. PubMed ID: 31402426
[TBL] [Abstract][Full Text] [Related]
4. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Nishida S; Tsuboi A; Tanemura A; Ito T; Nakajima H; Shirakata T; Morimoto S; Fujiki F; Hosen N; Oji Y; Kumanogoh A; Kawase I; Oka Y; Azuma I; Morita S; Sugiyama H
Medicine (Baltimore); 2019 Aug; 98(33):e16771. PubMed ID: 31415377
[TBL] [Abstract][Full Text] [Related]
5. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.
Stewart JH; Levine EA
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1671-6. PubMed ID: 22050015
[TBL] [Abstract][Full Text] [Related]
6. Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by
Yang J; Jones MS; Ramos RI; Chan AA; Lee AF; Foshag LJ; Sieling PA; Faries MB; Lee DJ
Front Oncol; 2017; 7():61. PubMed ID: 28424760
[No Abstract] [Full Text] [Related]
7. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
8. Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
Moff SL; Corey GR; Gottfredsson M
Clin Infect Dis; 1999 Dec; 29(6):1569-70. PubMed ID: 10585816
[No Abstract] [Full Text] [Related]
9. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
[TBL] [Abstract][Full Text] [Related]
10. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
11. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
12. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
13. Mumps virus and BCG vaccine in metastatic melanoma.
Minton JP
Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
[No Abstract] [Full Text] [Related]
14. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
15. Intralesional immunotherapy of melanoma with BCG.
Rosenberg SA; Rapp HJ
Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
[TBL] [Abstract][Full Text] [Related]
16. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in malignant melanomaa.
Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
[TBL] [Abstract][Full Text] [Related]
18. Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.
Kibbi N; Ariyan S; Faries M; Choi JN
J Immunother; 2015; 38(9):371-5. PubMed ID: 26448581
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
20. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]